Nuzenio

Hnscc

Hnscc news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Dostarlimab Monotherapy Elicits Responses in First-Line PD-L1-Positive HNSCC - OncLiveOncLive · Fri, 07 Aug 2026 15:25:50 GMTUnpacking Subgroup Data With First-Line Ipatasertib Plus Pembrolizumab in HNSCC - OncLiveOncLive · Thu, 06 Aug 2026 22:53:51 GMTDr Thomas on the Safety Profile of Frontline Ipatasertib Plus Pembrolizumab in HNSCC - OncLiveOncLive · Thu, 06 Aug 2026 21:37:16 GMTLow Tumor PD-L1 Expression Identifies Responders to Neoadjuvant Leukocyte Interleukin Injection in Locally Advanced HNSCC - OncLiveOncLive · Tue, 04 Aug 2026 07:00:00 GMTSubcutaneous Amivantamab Receives FDA Priority Review in R/M HNSCC - CancerNetworkCancerNetwork · Fri, 31 Jul 2026 17:08:12 GMTFDA Grants Priority Review to Subcutaneous Amivantamab for Advanced HNSCC - Targeted OncologyTargeted Oncology · Thu, 30 Jul 2026 20:09:42 GMT

Timeline

Fri, 07 Aug 2026 15:25:50 GMTDostarlimab Monotherapy Elicits Responses in First-Line PD-L1-Positive HNSCC - OncLive
Thu, 06 Aug 2026 22:53:51 GMTUnpacking Subgroup Data With First-Line Ipatasertib Plus Pembrolizumab in HNSCC - OncLive
Thu, 06 Aug 2026 21:37:16 GMTDr Thomas on the Safety Profile of Frontline Ipatasertib Plus Pembrolizumab in HNSCC - OncLive
Tue, 04 Aug 2026 07:00:00 GMTLow Tumor PD-L1 Expression Identifies Responders to Neoadjuvant Leukocyte Interleukin Injection in Locally Advanced HNSCC - OncLive
Fri, 31 Jul 2026 17:08:12 GMTSubcutaneous Amivantamab Receives FDA Priority Review in R/M HNSCC - CancerNetwork
Thu, 30 Jul 2026 20:09:42 GMTFDA Grants Priority Review to Subcutaneous Amivantamab for Advanced HNSCC - Targeted Oncology

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Hnscc.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.